Scilex Holding (SCLX) Cash from Financing Activities (2020 - 2026)
Scilex Holding (SCLX) recorded quarterly Cash from Financing Activities of $9.1 million in Q1 2026, down 47.81% quarter-over-quarter from $17.5 million in Q4 2025, and up 396.5% on a YoY basis from $1.8 million in Q1 2025.
Scilex Holding (SCLX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Scilex Holding's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $9.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 396.5% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $6.8 million (up 167.54% YoY), while the FY2025 annual figure was -$5.5 million, up 69.88% from the prior year.
- Cash from Financing Activities was $9.1 million for Q1 2026 at Scilex Holding, down from $17.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $43.5 million in Q2 2023 to a low of -$38.9 million in Q3 2023.
- Historically, Cash from Financing Activities has averaged $1.8 million across 5 years, with a median of -$3.1 million in 2025.
- Biggest YoY gain for Cash from Financing Activities was 1849.77% in 2023; the steepest drop was 466.26% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at $426000.0 in 2022, then jumped by 1849.77% to $8.3 million in 2023, then plunged by 186.48% to -$7.2 million in 2024, then soared by 343.91% to $17.5 million in 2025, then tumbled by 47.81% to $9.1 million in 2026.
- The last three Cash from Financing Activities figures came in at $9.1 million (Q1 2026), $17.5 million (Q4 2025), and -$11.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 366.70 Mn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | -3.47 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 530.00 Mn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 919.00 Mn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | -1.56 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn | 9.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.14 Mn |
| Mar 31, 2026 | 9.14 Mn |
| Dec 31, 2025 | 17.52 Mn |
| Dec 31, 2025 | 17.52 Mn |
| Sep 30, 2025 | -11.30 Mn |
| Sep 30, 2025 | -11.30 Mn |
| Jun 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -8.60 Mn |
| Mar 31, 2025 | -3.08 Mn |
| Mar 31, 2025 | -3.08 Mn |
| Dec 31, 2024 | -7.18 Mn |
| Dec 31, 2024 | -7.18 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Mar 31, 2024 | -11.20 Mn |
| Mar 31, 2024 | -11.20 Mn |
| Dec 31, 2023 | 8.31 Mn |
| Dec 31, 2023 | 8.31 Mn |